SCHEMBL2910705

SCHEMBL2910705

CC1(c2cc([N+](=O)[O-])ccc2OC(=O)O)CCOC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
BACE1 P56817 2/20 0.40
BACE2 Q9Y5Z0 2/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40
AKR1B1 P15121 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HTT P42858 3/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 2/20 0.39
PKM P14618 2/20 0.39
PAX8 Q06710 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910703 1.00 SMN1; SMN2 (0.48) SMN1; SMN2BACE1BACE2KMT2ALMNA
SCHEMBL2910700 0.93 SMN1; SMN2 (0.46) SMN1; SMN2BACE1BACE2KMT2ALMNA
SCHEMBL31441615 0.90 SMN1; SMN2 (0.44) SMN1; SMN2KMT2ALMNAALDH1A1AKR1B1
SCHEMBL9938240 0.87 ALDH1A1 (0.42) SMN1; SMN2KMT2ALMNAALDH1A1AKR1B1
SCHEMBL9938244 0.87 ALDH1A1 (0.42) SMN1; SMN2KMT2ALMNAALDH1A1AKR1B1
SCHEMBL4332383 0.79 BACE2 (0.44) SMN1; SMN2BACE1BACE2LMNAALDH1A1
SCHEMBL3639263 0.73 HTT (0.47) SMN1; SMN2KMT2ALMNAALDH1A1HTT
SCHEMBL3135666 0.72 ALDH1A1 (0.55) KMT2ALMNAALDH1A1HTTMAPK1
SCHEMBL3135676 0.72 ALDH1A1 (0.55) KMT2ALMNAALDH1A1HTTMAPK1
SCHEMBL1249807 0.71 HTT (0.58) SMN1; SMN2KMT2ALMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637528-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2010-09-01 EP disclosed
EP-1637528-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed
EP-1136479-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2005-12-28 EP disclosed
EP-0833826-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2002-01-23 EP disclosed
EP-1136479-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2001-09-26 EP disclosed
US-5990155-A VIRICIDES AGAINST THE HIV-1 AND HIV-2 VIRUSES; REVERSE TRANSCRIPTASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-11-23 US disclosed
EP-0833826-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 1998-04-08 EP disclosed
US-5691372-A Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-11-25 US disclosed
WO-1996033187-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1996-10-24 WO disclosed